CliffBio
small molecule

MOVANTIK

NALOXEGOL OXALATE

Loss of exclusivityApril 2032latest FDA-listed patent expiry
CompanyAVERITAS PHARMA INC →See this company's full patent-cliff portfolio

Drug detail

Brand nameMOVANTIK
Active ingredientNALOXEGOL OXALATE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusRX

Listed patents

PatentExpiresType
9012469April 2032substance, product
7786133September 2028substance, product

More from AVERITAS PHARMA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MOVANTIK patent cliff — loss of exclusivity April 2032 | CliffBio